Our Firm

Value Investor Insight—Investing in Healthcare an Interview with Robert Klaber

Portfolio Manager of the Parnassus Fund, Robert Klaber, discusses his views on Healthcare with Value Investor Insight.

See the full story.

For current quarter-end standardized performance and disclosure information, please click here.

As of 06/30/2017, percentage of the Parnassus Fund represented by the companies in this article are as follows: AGN is 4.3%, GILD is 4.4% and NVS is 2.3% of TNA. Percentage of the Parnassus Core Equity Fund represented by the companies in this article are as follows: AGN is 3.5%, GILD is 4.8% and NVS is 2.8% of TNA. Percentage of the Parnassus Endeavor Fund represented by the companies in this article are as follows: AGN is 4.6%, GILD is 12.0% and NVS is 4.2% of TNA. Percentage of the Parnassus Asia Fund represented by the companies in this article are as follows: GILD is 4.7% of TNA. Percentage of the Parnassus Fixed Income Fund represented by the companies in this article are as follows: Allergan due 3/1/18 is 1.1%, Gilead due 4/1/2024 is 0.9% and Novartis due 11/20/2025 is 1.9% of TNA.